Targimmune Therapeutics AG
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Mar 2032
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 20, 2026The maintenance fee for Castration Resistant Prostate Cancer (US 11,679,160) comes due Dec 20, 2026. Unpaid by Jun 21, 2027, it lapses early.
- 1 fee due Feb 28, 2027The maintenance fee for Systems and Methods for Automatically Generating a Data Center Network Mapping for Automated Alarm Consolidation (US 11,743,104) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
- 1 fee due Jul 28, 2027The maintenance fee for Polyplex of Double-Stranded RNA and Polymeric Conjugate (US 10,543,232) comes due Jul 28, 2027. Unpaid by Jan 28, 2028, it lapses early.
- 1 fee due Aug 27, 2027The maintenance fee for Chimeric proteins for targeting dsRNA (US 11,912,747) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,006,406 | Egfr-Homing Double-Stranded RNA Vector for Systemic Cancer Treatment In force · High confidence | In force | High confidence | |
| US 10,543,232 | Polyplex of Double-Stranded RNA and Polymeric Conjugate In force · High confidence | In force | High confidence | |
| US 11,298,376 | Method of Treating Cancer In force · High confidence | In force | High confidence | |
| US 10,278,991 | Polyethyleneimine Polyethyleneglycol Vectors In force · High confidence | In force | High confidence | |
| US 11,679,160 | Castration Resistant Prostate Cancer In force · High confidence | In force | High confidence | |
| US 11,743,104 | Systems and Methods for Automatically Generating a Data Center Network Mapping for Automated Alarm Consolidation In force · High confidence | In force | High confidence | |
| US 11,912,747 | Chimeric proteins for targeting dsRNA In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 7: 1 lapsed for an unpaid fee · 2 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 2 no status recorded